First Manhattan’s Melinta Therapeutics MLNT Stock Holding History
Bought
Maintained
Sold
Other funds holding MLNT
First Manhattan's MLNT Position: Q1 2019 in Review
First Manhattan sold out of Melinta Therapeutics (MLNT) in Q1 2019, closing a stake of 188,985 shares — an estimated $749K sold.
First Manhattan first reported a position in MLNT in Q2 2018 and held it in 3 quarters. The position peaked at $7.62M in Q2 2018. 52 funds tracked by Wall St. Rank hold MLNT as of Q1 2019.
- First Manhattan reported no remaining Melinta Therapeutics position as of Q1 2019 after selling out during the quarter.
- First Manhattan sold 188,985 Melinta Therapeutics shares in Q1 2019, an estimated $749K.
- First Manhattan first reported a position in Melinta Therapeutics in Q2 2018 and held it in 3 quarters.
- First Manhattan's Melinta Therapeutics position peaked at $7.62M in Q2 2018.
- 52 funds tracked by Wall St. Rank held Melinta Therapeutics as of Q1 2019.
Based on First Manhattan's 13F filing for Q1 2019, filed 12 Apr 2019.